Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy
- Autor
- JELOVAC, Danijela1 ; ARMSTRONG, Deborah K1
[1] The Johns Hopkins Kimmel Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 190, Baltimore, MD 21231, United States - Fuente
Current pharmaceutical design (Print). 2012, Vol 18, Num 25, pp 3812-3815, 4 p ; ref : 23 ref
- ISSN
- 1381-6128
- Campo Científico
- Pharmacology drugs
- Editor
- Bentham, Sharjah
- País de la publicación
- United Arab Emirates
- Tipo de documento
- Article
- Idioma
- English
- Palabra clave de autor
- and epithelial ovarian cancer farletuzumab
- Palabra clave (fr)
- Anticancéreux Article synthèse Cancer de l'ovaire Carcinome de l'ovaire Farletuzumab Anticorps monoclonal Cancer Pathologie de l'appareil génital femelle Pathologie des ovaires Tumeur maligne
- Palabra clave (in)
- Antineoplastic agent Review Ovary cancer Ovary carcinoma Farletuzumab Monoclonal antibody Cancer Female genital diseases Ovarian diseases Malignant tumor
- Palabra clave (es)
- Anticanceroso Artículo síntesis Cáncer del ovario Carcinoma de ovario Farletuzumab Anticuerpo monoclonal Cáncer Aparato genital hembra patología Ovario patología Tumor maligno
- Clasificación
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20C Female genital diseases / 002B20C02 Tumors
- Disciplina
- Gynecology. Andrology. Obstetrics
- Procedencia
- Inist-CNRS
- Base de datos
- PASCAL
- Identificador INIST
- 26259021
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Acceso al documento
Install on your browser
DOI
10.2174/138161212802002698 
https://dx.doi.org/10.2174/138161212802002698
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3812\";s:8:\"\u0000*\u0000epage\";s:4:\"3815\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JELOVAC\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Danijela\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:20:\"ARMSTRONG, Deborah K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Panist
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3812\";s:8:\"\u0000*\u0000epage\";s:4:\"3815\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JELOVAC\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Danijela\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:20:\"ARMSTRONG, Deborah K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Istex
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Acceso mediante Unpaywall
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3812\";s:8:\"\u0000*\u0000epage\";s:4:\"3815\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JELOVAC\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Danijela\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:20:\"ARMSTRONG, Deborah K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Europe PubMed Central
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3812\";s:8:\"\u0000*\u0000epage\";s:4:\"3815\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JELOVAC\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Danijela\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:20:\"ARMSTRONG, Deborah K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante Base Search
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161212802002698\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"18\";s:8:\"\u0000*\u0000issue\";s:2:\"25\";s:8:\"\u0000*\u0000spage\";s:4:\"3812\";s:8:\"\u0000*\u0000epage\";s:4:\"3815\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"JELOVAC\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Danijela\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:20:\"ARMSTRONG, Deborah K\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:100:\"Role of Farletuzumab in Epithelial Ovarian Carcinoma : Advances in Epithelial Ovarian Cancer Therapy\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Acceso mediante arXiv
